Ceftobiprole: A new β-lactam antibiotic

International Journal of Clinical Practice

Volumn 63, Issue 6, 2009, Pages 930-943

  Stein, R A ^a,c   Goetz, R M ^a   Ganea, G M ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFDITOREN PIVOXIL; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; GATIFLOXACIN; GEMIFLOXACIN; LINEZOLID; MOXIFLOXACIN; TELITHROMYCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLIN BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; HEADACHE; HUMAN; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; OSTEOMYELITIS; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SEPTICEMIA; SKIN ABSCESS; SKIN INFECTION; STREPTOCOCCUS PNEUMONIA; TASTE DISORDER; VOMITING; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; METABOLISM; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DIABETIC FOOT; DISEASE MODELS, ANIMAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCAL INFECTIONS;

EID: 65649151323     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02041.x     Document Type: Article

References (73)

1. Rossolini GM. Redesigning β-lactams to combat resistance: summary and conclusions. Clin Microbiol Infect 2007 13 (Suppl. 2 30 3.
2. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963 1 : 904 7.
3. Crum NF. The emergence of severe, community-acquired methicillin- resistant Staphylococcus aureus infections. Scand J Infect Dis 2005 37 : 651 6.
4. Iversen N, Mellgren J, Baxter C et al. Prevalence of methicillin resistant Staphylococcus aureus (MRSA) colonization: a Patient and Employee Study in a 270-Bed Regional Referral Hospital. Am J Infection Control 2007 35 : E23 4.
5. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007 13 : 1840 6.
6. Boyce JM, Cookson B, Christiansen K et al. Methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2005 5 : 653 63.
7. Borg MA, de Kraker M, Scicluna E et al. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother 2007 60 : 1310 5.
8. Sader HS, Streit JM, Fritsche T et al. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006 12 : 844 52.
9. Goldstein FW, Garau J. 30 years of penicillin-resistant S. pneumoniae: myth or reality? Lancet 1997 350 : 233 4.
10. Craig WA. Does the dose matter? Clin Inf Dis 2001 33 (Suppl. 2 S233 7.
11. Bertrand X, Thouverez M, Talon D et al. Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units. Intensive Care Med 2001 27 : 1263 8.
12. Deresinski SC. Ceftobiprole: breaking therapeutic dogmas of the beta-lactam class. Diagn Microbiol Infect Dis 2008 61 : 82 5.
13. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008 61 : 86 95.
14. Page MGP. Ceftobiprole - a case study. Expert Opin Drug Discov 2007 2 : 115 29.
15. Black D. Ceftobiprole: the next fourth-generation cephalosporin. D-Zone 2007 36 (Suppl. 5 S17 20.
16. Srinivasan V, McGowan JE Jr., McAllister S. In vitro activity of ceftobiprole against coagulase-negative staphylococci isolated in the USA. Int J Antimicrob Agents 2008 31 : 294 6.
17. Entenza JM, Hohl P, Heinze-Krauss I et al. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 2002 46 : 171 7.
18. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006 50 : 3959 62.
19. Vaudaux P, Gjinovci A, Bento M et al. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005 49 : 3789 93.
20. Kosowska K, Hoellman DB, Lin G et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005 49 : 1932 42.
21. Zhanel GG, Lam A, Schweizer F et al. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008 9 : 245 54.
22. Anderson SD, Gums JD. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008 42 : 806 16.
23. Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin Microbiol Infect 2006 12 (Suppl. 2 11 6.
24. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008 47 : 21 33.
25. Schmitt-Hoffmann A, Nyman L, Roos B et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004 48 : 2576 80.
26. Schmitt-Hoffmann A, Roos B, Schleimer M et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004 48 : 2570 5.
27. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care 2008 12 (Suppl. 4 S2.
28. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997 27 : 29 33.
29. Noel GJ, Strauss RS, Amsler K et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008 52 : 37 44.
30. Lodise TP Jr., Pypstra R, Kahn JB et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007 51 : 2378 87.
31. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008 46 : 647 55.
32. Waxman DJ, Stromninger JL. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem 1983 52 : 825 69.
33. Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 1984 158 : 513 6.
34. Palavecino E. Clinical, epidemiological, and laboratory aspects of methicillin-resistant Staphylococcus aureus (MRSA) infections. Methods Mol Biol 2007 391 : 1 19.
35. de Jonge BL, Tomasz A. Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis. Antimicrob Agents Chemother 1993 37 : 342 6.
36. Lim D, Strynadka NC. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 2002 9 : 870 6.
37. Page MGP. Anti-MRSA β-lactams in development. Curr Opin Pharmacol 2006 6 : 480 5.
38. Hebeisen P, Heinze-Krauss I, Angehrn P et al. In vitro and in vivo properties of Ro 63- 9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001 45 : 825 36.
39. Davies TA, Page MG, Shang W et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemoter 2007 51 : 2621 4.
40. Bogdanovich T, Clark C, Ednie L et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2006 50 : 2050 7.
41. Banerjee R, Gretes M, Basuino L et al. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aures. Antimicrob Agents Chemother 2008 52 : 2089 96.
42. Bogdanovich T, Ednie LM, Shapiro S et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005 49 : 4210 9.
43. Jones ME. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007 13 (Suppl. 2 17 24.
44. Yun HC, Ellis MW, Jorgensen JH. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn Microbiol Infect Dis 2007 59 : 463 6.
45. Pillar CM, Aranza MK, Shah D. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008 61 : 595 602.
46. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007 58 : 363 5.
47. Ziglam H. Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother 2007 8 : 2279 92.
48. Arias CA, Singh KV, Panesso D et al. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother 2007 51 : 2043 7.
49. Desphanade LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003 9 : 1120 4.
50. Davies T, Sahm D, Flamm R et al. Activity of Ceftobiprole Against Pseudomonas Aeruginosa Clinical Isolates From Europe Collected in 2005-2006. Abstract number: 1733-1522 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany : ICC, 31 March-4 April 2007.
51. Walkty A, Decorby M, Nichol K et al. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J Antimicrob Chemother 2008 62 : 206 8.
52. Rouse MS, Hein MM, Anguita-Alonso P. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn Microbiol Infect Dis 2006 55 : 333 6.
53. Issa NC, Rouse MS, Piper KE. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis 2004 48 : 73 5.
54. Jones RN, Deshpande LM, Mutnick AH et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002 50 : 915 32.
55. Thamlikitkul V, Trakulsomboon S. In vitro activity of ceftobiprole against Burkholderia pseudomallei. J Antimicrob Chemother 2008 61 : 460 1.
56. Dance DA, Wuthiekanun V, Chaowagul W et al. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J Antimicrob Chemother 1991 28 : 321 4.
57. Wuthiekanun V, Cheng AC, Chierakul W et al. Trimethoprim-sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother 2005 55 : 1029 31.
58. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004 54 : 1134 8.
59. Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftbiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis 2007 58 : 133 6.
60. Wootton MN, Bowker KE, Holt HA et al. BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother 2002 49 : 535 9.
61. Cremieux AC, Maziere B, Vallois JM et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989 159 : 938 44.
62. Guerrero MLF, de Gorgolas M. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis. J Antimicrob Chemother 2006 58 : 1066 9.
63. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005 49 : 884 8.
64. Lucet JC, Herrmann M, Rohner P et al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990 34 : 2312 7.
65. Chuard C, Vaudaux P, Waldvogel FA, Lew DP. Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics. Antimicrob Agents Chemother 1993 37 : 625 32.
66. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990 162 : 96 102.
67. Yin LY, Calhoun JH, Thomas JK et al. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of methicillin-resistant Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother 2008 52 : 1618 22.
68. Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 2007 60 : 594 8.
69. Azoulay-Dupuis A, Bedos JP, Mohler J et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother 2004 48 : 1105 11.
70. Nicholson SC, Strauss RA, Michiels B et al. Efficacy of Ceftobiprole (BPR) Compared to Ceftriaxone (CTX) +-- Linezolid (L) for the Treatment of Hospitalized Community-Acquired Pneumonia. Poster # C16 Presented at the American Thoracic Society International Conference. Toronto, 16-21 May 2008.
71. Strauss RS, Bagchi P, Noel GJ et al. Ceftobiprole Compared to Vancomycin Plus Ceftazidime in the Treatment of Patients With Diabetic Foot Infections. Presented at the 45th Annual Meeting of the Infectious Diseases Society of America (IDSA), 4-7 October 2007. San Diego, CA, Poster 1086.
72. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis 2008 61 : 103 9.
73. Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob Agents Chemother 2002 46 : 871 4.